ASCO® 2026 Highlights: Presenter Vignette – Van Morris
Van Morris
MD
MD Anderson Cancer Center
3504
SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated MSS, BRAFV600E metastatic colorectal cancer (mCRC).
This program has been made possible through unrestricted support from